Literature DB >> 11437592

High-level soluble production and characterization of porcine ribonuclease inhibitor.

T A Klink1, A M Vicentini, J Hofsteenge, R T Raines.   

Abstract

Ribonucleases can be cytotoxic if they retain their ribonucleolytic activity in the cytosol. The cytosolic ribonucleolytic activity of ribonuclease A (RNase A) and other pancreatic-type ribonucleases is limited by the presence of excess ribonuclease inhibitor (RI). RI is a 50-kDa cytosolic scavenger of pancreatic-type ribonucleases that competitively inhibits their ribonucleolytic activity. RI had been overproduced as inclusion bodies, but its folding in vitro is inefficient. Here, porcine RI (pRI) was overproduced in Escherichia coli using the trp promoter and minimal medium. This expression system maintains pRI in the soluble fraction of the cytosol. pRI was purified by affinity chromatography using immobilized RNase A and by anion-exchange chromatography. The resulting yield of 15 mg of purified RI per liter of culture represents a 60-fold increase relative to previously reported recombinant DNA systems. Differential scanning calorimetry was used to study the thermal denaturation of pRI, RNase A, and the pRI-RNase A complex. The conformational stability of the complex is greater than that of the individual components. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437592     DOI: 10.1006/prep.2001.1422

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  11 in total

Review 1.  Ribonuclease inhibitor: structure and function.

Authors:  Kimberly A Dickson; Marcia C Haigis; Ronald T Raines
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2005

2.  Human ribonuclease with a pendant poly(ethylene glycol) inhibits tumor growth in mice.

Authors:  Thomas J Rutkoski; John A Kink; Laura E Strong; Ronald T Raines
Journal:  Transl Oncol       Date:  2013-08-01       Impact factor: 4.243

3.  Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein.

Authors:  R Jeremy Johnson; Jason G McCoy; Craig A Bingman; George N Phillips; Ronald T Raines
Journal:  J Mol Biol       Date:  2007-02-09       Impact factor: 5.469

4.  A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells.

Authors:  Trish T Hoang; I Caglar Tanrikulu; Quinn A Vatland; Trieu M Hoang; Ronald T Raines
Journal:  Mol Cancer Ther       Date:  2018-10-03       Impact factor: 6.261

5.  Intraspecies regulation of ribonucleolytic activity.

Authors:  R Jeremy Johnson; Luke D Lavis; Ronald T Raines
Journal:  Biochemistry       Date:  2007-10-23       Impact factor: 3.162

6.  Interaction of onconase with the human ribonuclease inhibitor protein.

Authors:  Rebecca F Turcotte; Ronald T Raines
Journal:  Biochem Biophys Res Commun       Date:  2008-10-16       Impact factor: 3.575

7.  Functional expression of recombinant human ribonuclease/angiogenin inhibitor in stably transformed Drosophila melanogaster S2 cells.

Authors:  Jong-Hwa Park; In-Sook Hwang; Kyung-Il Kim; Jong-Min Lee; Young-Min Park; Chang-Ho Park; In Sik Chung
Journal:  Cytotechnology       Date:  2008-01-25       Impact factor: 2.058

8.  Reducing conditions are the key for efficient production of active ribonuclease inhibitor in Escherichia coli.

Authors:  Juozas Siurkus; Peter Neubauer
Journal:  Microb Cell Fact       Date:  2011-05-10       Impact factor: 5.328

9.  Heterologous production of active ribonuclease inhibitor in Escherichia coli by redox state control and chaperonin coexpression.

Authors:  Juozas Šiurkus; Peter Neubauer
Journal:  Microb Cell Fact       Date:  2011-08-08       Impact factor: 5.328

10.  A blueprint for academic laboratories to produce SARS-CoV-2 quantitative RT-PCR test kits.

Authors:  Samantha J Mascuch; Sara Fakhretaha-Aval; Jessica C Bowman; Minh Thu H Ma; Gwendell Thomas; Bettina Bommarius; Chieri Ito; Liangjun Zhao; Gary P Newnam; Kavita R Matange; Hem R Thapa; Brett Barlow; Rebecca K Donegan; Nguyet A Nguyen; Emily G Saccuzzo; Chiamaka T Obianyor; Suneesh C Karunakaran; Pamela Pollet; Brooke Rothschild-Mancinelli; Santi Mestre-Fos; Rebecca Guth-Metzler; Anton V Bryksin; Anton S Petrov; Mallory Hazell; Carolyn B Ibberson; Petar I Penev; Robert G Mannino; Wilbur A Lam; Andrés J Garcia; Julia Kubanek; Vinayak Agarwal; Nicholas V Hud; Jennifer B Glass; Loren Dean Williams; Raquel L Lieberman
Journal:  J Biol Chem       Date:  2020-09-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.